LLY241206C860000
- 1.60
- +0.64+66.67%
Eli Lilly and Co Newsroom
Will Trump Nix Biden's Coverage Plan for Weight-loss Drugs? It'll Be a Close Call.
Sector Update: Health Care
10 Health Care Stocks Whale Activity In Today's Session
Stock Of The Day: Where Will The Eli Lilly Rally End?
S&P and Nasdaq on Track for Third Record Close This Week | Live Stock
Zepbound Tops Wegovy for Weight Loss in Eli Lilly Study
Decoding Eli Lilly's Options Activity: What's the Big Picture?
Novo Nordisk Shares Dipped on Eli Lilly's Zepbound Results -- Market Talk
Eli Lilly and Co announced the comparative trial results: Zepbound's weight-loss effect is better than Novo Nordisk's Wegovy.
eli lilly and co announced on Wednesday that in a comparative trial, its weight loss drug Zepbound had a greater weight loss effect than the competitor novo-nordisk a/s's similar drug Wegovy; eli lilly is still evaluating the trial results, the company stated that it plans to publish them in a peer-reviewed journal and present them at medical conferences next year.
Better than Wegovy! eli lilly and co's weight loss drug Zepbound averaged a 20% weight loss over 72 weeks, with a 2.5% pre-market surge.
Participants using Wegovy from novo-nordisk a/s only experienced a 14% reduction. This result presents eli lilly and co with an opportunity to surpass, especially with the obesity drug market expected to reach 130 billion USD by the end of this decade.
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
Update: Eli Lilly Says Its Zepbound Showed 47% 'Greater Relative Weight Loss' Against Wegovy in Phase 3b Trial
Express News | Rondo Therapeutics Announces Collaboration With Lilly to Develop Novel Cd28 Bispecific Antibodies for Solid Tumors
US Morning News Call | Stock Index Futures Climb on Positive Earnings, Focus Shifts to Upcoming Speech by Powell
Eli Lilly (LLY.US) outperformed Novo Nordisk (NVO.US) in the comparative trial showing that Zepbound is superior to Wegovy.
Eli Lilly and Co (LLY.US) announced that its weight loss drug Zepbound performed better in the first head-to-head trial compared to the competitor novo-nordisk a/s (NVO.US) Wegovy.
Eli Lilly and Company's (NYSE:LLY) Intrinsic Value Is Potentially 64% Above Its Share Price
Eli Lilly's Zepbound Beats Novo Nordisk's Wegovy in First Head-to-Head Study
Express News | Eli Lilly Shares up 1.3% Premarket After Co's Weight-Loss Drug Tops Rival Wegovy in Head-to-Head Study
Express News | Eli Lilly Announced Topline Results From The SURMOUNT-5 Phase 3b Open-label Randomized Clinical Trial
Express News | Lilly: At 72 Weeks, Zepbound Beat Wegovy on Both Primary Endpoint, All Five Key Secondary Endpoints in Trial